For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …

Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or
ischemic events in patients with coronary artery disease treated with percutaneous coronary …

Background: Long-term outcomes of antiplatelet monotherapy in patients who receive
percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal …

Importance The role of ticagrelor with or without aspirin after coronary artery bypass graft
surgery remains unclear. Objective To compare the risks of vein graft failure and bleeding …

Background Phase II randomized controlled trials (RCTs) on factor (F) XI inhibitors have
shown promising results but they were burdened by low statistical power for clinical …

Precision medicine is a medical model that proposes the customization of medical
treatments to the individual patient, as opposed to a one-drug-fits-all model. Such a …

Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Dual antiplatelet therapy (DAPT) represents the standard of care for patients undergoing
percutaneous coronary intervention (PCI). Increasing evidence indicates that a “one-size-fits …

Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …

Background Following percutaneous coronary intervention with stent placement to treat
acute coronary syndromes, international clinical guidelines generally recommend dual …